Synonyms: compound 70 [WO2013019561A1] | KPT-330 | KPT330 | Nexpovio® | Xpovio®
selinexor is an approved drug (FDA (2019), EMA (2021))
Compound class:
Synthetic organic
Comment: Selinexor (KPT-330) is an inhibitor of the nuclear export protein XPO1 (a.k.a. exportin 1) that is being developed as an anti-neoplastic agent by Karyopharm Therapeutics. It is a first-in-class inhibitor that exploits a novel mechanism of action compared to existing chemotherapeutics [2,7-8]. The chemical structure is claimed in patent WO2013019561A1 (as compound 70) [9].
|
|
Immunopharmacology Comments |
Selinexor (KPT-330) has been found to reduce pro-inflammatory cytokine production (TNF-α and IL-6), decrease macrophage and PMN subpopulations in the peritoneal cavity, and thereby protect against sepsis in a LPS-induced sepsis model in vivo [11]. |